PPT-NRTI-sparing

SPARTAN PROGRESS NEAT001ANRS 14 3 MODERN Raffi F Lancet 2014384194251 NEAT 001 ANRS 143 Design Objective Non inferiority of RAL compared to TDFFTC of participants reaching the primary endpoint by week 96 estimated by the KaplanMeier method in intentiontotreat analysis . Jim Demarest. ,. 1. Mark Underwood,. 2. Marty St Clair,. 2. . David Dorey,. 3. Steve Almond,. 3. Robert Cuffe,. 4. . Dannae Brown,. 5. Garrett Nichols. 6. . 1. ViiV Healthcare, Global R&D, Research Triangle Park, NC, USA; . Allan Stewart, MD., Jonathan A. Yang, MD; Mark J. Russo, MD/MPH; Alexander . Iribarne. , MD; Brendan F. Scully; Rachel . Easterwood. ; Craig R. Smith, MD; Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY. Memantine. and IMRT Planning for Hippocampus Sparing in Patients Receiving Whole Brain Radiotherapy for Brain Metastases . Alexander Slade, PhD and Sinisa Stanic, MD. Carle Cancer Center and University of Illinois College of Medicine at Urbana-Champaign. ZDV/3TC . vs. TDF + FTC. Study 934. ABC/3TC . vs. TDF/FTC. HEAT Study. ACTG A5202 Study. ASSERT Study. FTC/TDF vs FTC/TAF. Studies GS-US-292-0104 and GS-US-292-0111. GS-US-292-0104/0111. Design. Objective. Chief, Division of Infectious Diseases. Weill Medical College of Cornell University. New York, New York. Antiretroviral Therapy: . New Drugs and New Guidelines. FORMATTED: . 03/08/16. Chicago, Illinois: May 9, 2016. New Treatments for HIV. C. Ryan Tomlin, . Pharm.D. ., BCPS, AAHIVP. Mercy Health Saint Mary’s. Grand Rapids, Michigan. Outline. Newly Released Antiretroviral Medications. Isentress. HD. ® (. raltegravir. Drew Lambert, . PharmD. lambertd@husson.edu. Husson University School of Pharmacy. 1. PollEverywhere. - Text . DREWLAMBERT221 to 22333 to join. You . can respond at . PollEv.com/drewlambert221. I have no conflicts of interest.. ATV/r 300/100 mg QD 3TC 300 mg QD. N = 133. N = 133. Continuación ATV/r 300/100 mg QD 2 NRTI . Diseño. Randomización. 1:1. Etiqueta abierta. Objetivo. Endpoint. primario: proporción de pacientes sin fallo al tratamiento a S48 . Medical Director, Specialty . Services. Southwest CARE Center. Santa Fe, New Mexico. State-of-the-ART. . in . Antiretroviral . Management. FORMATTED: MM/DD/YY. New Orleans, Louisiana: December 15-17, 2015. Study. LPV/. r. bid + 3TC or FTC . qd. + NRTI. N =. 127. N =. 123. LPV/. r. bid + 3TC/FTC . qd. Design. Randomisation*. 1: 1. Open-label. Objective. Primary Endpoint :. proportion without treatment failure at W48 . Clinical Pharmacist – HIV Medicine. Outline. What is HIV?. Common Labs. Life Cycle and Medication Targets. Building an HIV regimen. HIV Guidelines. When to start treatment. What medications to start. TOTEM. Switching the NRTI Backbone to Tenofovir DF-Emtricitabine. TOTEM: Study Design. Source. : . Valantin. MA, et al. . J . Antimicrob. . Chemother. . 2010;65:556-61.. TDF-FTC + Continue . 3. rd. by Baseline NRTI Resistance . and Second-Line NRTI Use. Dannae. Brown,. 1. . Ruolan. Wang,. 2. Mark Underwood,. 2. Judy Hopking,. 3. Maria Claudia Nascimento,. 4. . Michael Aboud,. 4. . Jörg. Research . designs, methods, and study execution . Michael C. Rowbotham, MD. Chief Research Officer, Sutter Health. Adjunct Professor, UCSF Anesthesia. Professor Emeritus, UCSF Neurology. What does ‘opioid sparing’ mean and what are the...